{"result": "(\"entity\"<|>JWM<|>ORGANIZATION<|>JWM is a lender involved in the clinical practice guideline for pheochromocytoma and paraganglioma.)\n##\n(\"entity\"<|>DUH QY<|>ORGANIZATION<|>DUH QY is a lender mentioned in the context of pheochromocytoma and paraganglioma guidelines.)\n##\n(\"entity\"<|>EISENHOFER G<|>ORGANIZATION<|>Eisenhofer G is a lender associated with the clinical practice guideline for pheochromocytoma and paraganglioma.)\n##\n(\"entity\"<|>GIMENEZ-ROQUEPLO AP<|>ORGANIZATION<|>Gimenez-Roqueplo AP is a lender involved in the clinical practice guideline for pheochromocytoma and paraganglioma.)\n##\n(\"entity\"<|>GREBE SKG<|>ORGANIZATION<|>Grebe SKG is a lender mentioned in the context of pheochromocytoma and paraganglioma guidelines.)\n##\n(\"entity\"<|>MURAD MH<|>ORGANIZATION<|>Murad MH is a lender associated with the clinical practice guideline for pheochromocytoma and paraganglioma.)\n##\n(\"entity\"<|>ENDOCRINE SOCIETY<|>ORGANIZATION<|>The Endocrine Society is an organization that published the clinical practice guideline for pheochromocytoma and paraganglioma.)\n##\n(\"entity\"<|>YOUNG WF JR<|>PERSON<|>Young WF Jr is a medical professional who has contributed to the literature on pheochromocytoma and paraganglioma.)\n##\n(\"entity\"<|>KASPER DL<|>PERSON<|>Kasper DL is an editor of the Harrison Principles of Internal Medicine, which discusses pheochromocytoma.)\n##\n(\"entity\"<|>HAUSER SL<|>PERSON<|>Hauser SL is an editor of the Harrison Principles of Internal Medicine, which discusses pheochromocytoma.)\n##\n(\"entity\"<|>JAMESON JL<|>PERSON<|>Jameson JL is an editor of the Harrison Principles of Internal Medicine, which discusses pheochromocytoma.)\n##\n(\"entity\"<|>FAUCI AS<|>PERSON<|>Fauci AS is an editor of the Harrison Principles of Internal Medicine, which discusses pheochromocytoma.)\n##\n(\"entity\"<|>LONGO DL<|>PERSON<|>Longo DL is an editor of the Harrison Principles of Internal Medicine, which discusses pheochromocytoma.)\n##\n(\"entity\"<|>LOSCAZO J<|>PERSON<|>Loscazo J is an editor of the Harrison Principles of Internal Medicine, which discusses pheochromocytoma.)\n##\n(\"entity\"<|>UPTODATE INC<|>ORGANIZATION<|>UpToDate Inc is a medical resource that provides literature on the clinical presentation and treatment of pheochromocytoma.)\n##\n(\"entity\"<|>MEXICO DF<|>GEO<|>Mexico DF is the location where the Harrison Principles of Internal Medicine was published.)\n##\n(\"entity\"<|>PHILADELPHIA<|>GEO<|>Philadelphia is the location where the Williams Textbook of Endocrinology was published.)\n##\n(\"entity\"<|>WALTHAM MA<|>GEO<|>Waltham, MA is the location of UpToDate Inc, which provides medical literature on pheochromocytoma.)\n##\n(\"relationship\"<|>YOUNG WF JR<|>UPTODATE INC<|>Young WF Jr has contributed to the literature provided by UpToDate Inc on pheochromocytoma<|>7)\n##\n(\"relationship\"<|>JWM<|>ENDOCRINE SOCIETY<|>JWM is involved in the clinical practice guideline published by the Endocrine Society<|>6)\n##\n(\"relationship\"<|>DUH QY<|>ENDOCRINE SOCIETY<|>DUH QY is involved in the clinical practice guideline published by the Endocrine Society<|>6)\n##\n(\"relationship\"<|>EISENHOFER G<|>ENDOCRINE SOCIETY<|>Eisenhofer G is involved in the clinical practice guideline published by the Endocrine Society<|>6)\n##\n(\"relationship\"<|>GIMENEZ-ROQUEPLO AP<|>ENDOCRINE SOCIETY<|>Gimenez-Roqueplo AP is involved in the clinical practice guideline published by the Endocrine Society<|>6)\n##\n(\"relationship\"<|>GREBE SKG<|>ENDOCRINE SOCIETY<|>Grebe SKG is involved in the clinical practice guideline published by the Endocrine Society<|>6)\n##\n(\"relationship\"<|>MURAD MH<|>ENDOCRINE SOCIETY<|>Murad MH is involved in the clinical practice guideline published by the Endocrine Society<|>6)\n##\n(\"relationship\"<|>KASPER DL<|>HARRISON PRINCIPLES OF INTERNAL MEDICINE<|>Kasper DL is an editor of the Harrison Principles of Internal Medicine, which discusses pheochromocytoma<|>8)\n##\n(\"relationship\"<|>HAUSER SL<|>HARRISON PRINCIPLES OF INTERNAL MEDICINE<|>Hauser SL is an editor of the Harrison Principles of Internal Medicine, which discusses pheochromocytoma<|>8)\n##\n(\"relationship\"<|>JAMESON JL<|>HARRISON PRINCIPLES OF INTERNAL MEDICINE<|>Jameson JL is an editor of the Harrison Principles of Internal Medicine, which discusses pheochromocytoma<|>8)\n##\n(\"relationship\"<|>FAUCI AS<|>HARRISON PRINCIPLES OF INTERNAL MEDICINE<|>Fauci AS is an editor of the Harrison Principles of Internal Medicine, which discusses pheochromocytoma<|>8)\n##\n(\"relationship\"<|>LONGO DL<|>HARRISON PRINCIPLES OF INTERNAL MEDICINE<|>Longo DL is an editor of the Harrison Principles of Internal Medicine, which discusses pheochromocytoma<|>8)\n##\n(\"relationship\"<|>LOSCAZO J<|>HARRISON PRINCIPLES OF INTERNAL MEDICINE<|>Loscazo J is an editor of the Harrison Principles of Internal Medicine, which discusses pheochromocytoma<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: • Lenders JWM, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SKG, Murad MH, et al. Pheochromocytoma and paraganglioma:                           D.  Cocaína.\n       an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2014;99:1915-41.\n     • Neumann HPH. Feocromocitoma. En: Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscazo J, eds. Harrison Principios\n       de Medicina Interna. 19.ª edición en español. México DF: Mc Graw Hill; 2016. p. 2329-35.\n     • Young WF, Jr. Endocrine Hypertension. En: Melmed S, Polonsky KS, Larsen PR, Kronenberg HM, eds. Williams Textbook\n       of Endocrinology. 13.ª ed. Philadelphia: Elsevier; 2016. p. 556-88.\n     • Young WF, Jr. Clinical presentation and diagnosis of pheochromocytoma. UpToDate. Waltham, MA: UpToDate Inc. https://www.\n       uptodate.com. Literature review current through: Apr. 2019.\n     • Young WF, Jr, Kebebew E. Treatment of pheochromocytoma in adults. UpToDate. Waltham, MA: UpToDate Inc. https://www.uptodate.\n       com. Literature review current through: Apr. 2019.\n\n\n\n306                                                                                                                                                                                                                                                      307\n---\n                                                                                                                                                                        SUPRARRENALES                                  5\n\n\n\n58  Se realiza suprarrenalectomía bilateral tras el adecuado alfabloqueo. El informe                    ciona con feocromocitomas suprarrenales que presentan un fenotipo bioquímico suprarre-\n    anatomopatológico señala feocromocitoma bilateral. Las técnicas de                                  nal. El primer grupo incluye mutaciones germinales en SDHD, SDHC, SDHB, SDHAF2, SDHA,\n    inmunohistoqímica muestran SDHB positivo. ¿Qué estudio genético realizaría                          VHL, HIF2, FH gen codificante de fumarato hidratasa, EGLN1 (PHD2), EGLN2 (PHD1) y KIFB.\n    en primer lugar?                                                                                    El segundo grupo incluye mutaciones germinales en los genes RET, NF1, MAX y TMEM127.\n    A. Estudio del gen RET.                                                                             A la hora de interpretar los resultados, es importante tener en cuenta que la tasa de falsos\n    B. Estudio del gen SDHB.                                                                            positivos en la determinación de metanefrinas, tanto plasmáticas como urinarias, no es\n                                                                                                        despreciable (hasta un 19-21%). Antidepresivos tricíclicos, anfetaminas y cocaína pueden\n    C. Estudio del gen VHL.                                                                             dar falsos positivos.\n    D.  Estudio del gen SDHC.                                                                           Una vez confirmado el exceso de producción de catecolaminas con los test bioquímicos se\n    El estudio genético fue positivo. Respecto al seguimiento de esta paciente y sus                    deben realizar las pruebas de imagen para la localización del tumor. Habitualmente, la prime-\n59                                                                                                      ra prueba de imagen solicitada suele ser una TAC con contraste por su excelente resolución\n    familiares, señale la respuesta correcta:                                                           espacial, con una sensibilidad entre el 88% y el 100% y que permite detectar tumores de hasta\n    A. La paciente no necesita más seguimiento, ya que tras la intervención los marcadores              5 mm.\n        bioquímicos se han normalizado.                                                                 En los casos en los que no se detecte el tumor mediante pruebas de imagen anatómicas,\n    B. En pacientes con mutaciones en VHL se debe descartar la presencia de                             será necesaria la realización de pruebas de imagen funcionales. La prueba más clásica es\n        hemangioblastomas cerebrales y carcinoma renal.                                                 la gammagrafía con metayodobencilguanidina marcada con 123I (123I-MIBG). La MIBG es\n    C. En caso de mutación en el gen SDHD, la enfermedad se manifiesta con mayor frecuencia             un radiofármaco con estructura similar a la noradrenalina que es captado y almacenado\n        si se hereda de la madre.                                                                       en las células cromafines. Permite obtener imágenes en SPECT-TAC y proporciona informa-\n    D.  En caso de mutación en VHL, la probabilidad de que los hijos estén afectados es de un 25%.      ción tanto anatómica como funcional del tumor, pudiendo detectar tumores no detectados\n                                                                                                        en TAC/RMN. La sensibilidad de la MIBG varía entre el 85% y el 88% en feocromocitomas\n                                                                                                        y  entre el   56%   y  el 75%    en paragangliomas,        pero   tiene   una especificidad       mayor    que\n    COMENTARIO                                                                                          TAC/RMN, llegando\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}